US President Trump scheduled to sign an executive order on childhood vaccines (MRNA, NVAX) today, reports CBS citing sources

Executive orders touching vaccine policy sit in a category where the headline risk historically arrives before the substance: orders of this kind are often narrower than the framing suggests, are sometimes subject to legal challenge, and frequently delegate implementation to health agencies whose rulemaking runs on a slower calendar. For vaccine-exposed names the established pattern is an initial gap on the political optics, with the durable move hinging on what the order actually directs: changes to advisory committee composition, procurement, liability, or scheduling recommendations each carry different weight for revenue, and childhood schedule changes matter most for the paediatric franchise share rather than the broader pipeline. The named issuers have form here; pandemic-era experience showed how sensitive the group is to shifts in government posture toward vaccination, in both directions. The distinction worth drawing is between an order that alters federal purchasing or recommendations, which transmits to sales, and one that is largely symbolic, where the move has tended to fade. Follow-ons are the order text itself, any agency guidance that follows, and whether the congressional and legal response converts or blunts it. As a scheduled signing reported from sources, the detail is still to come.